

Lab Ref. No :	MR. DUMMY	Centre :	DR DANGS LAB
Name :	MR. DUMMY	Client :	DR DANGS LAB
Age / Gender :	34 Y 0 M 0 D /MALE	Collection Time :	05-07-2025 01:50 PM
Ref. By Dr :	SELF	Reporting Time :	05-07-2025 03:46 PM
		Report Status :	Final Report

DEPARTMENT OF BIOCHEMISTRY AND IMMUNOASSAYS

TEST (METHODOLOGY)	RESULT	UNIT	BIO. REF. INTERVAL
Lp-PLA2 (Lipoprotein associated phospholipase A2), Serum [CLIA]	150.00	ng/mL	<200

INTERPRETATION:

Elevated Lp-PLA2 levels may warrant further investigation and monitoring to identify and address any underlying cardiovascular issues.

LOW-RISK	< 200 ng/mL	Minimal arterial inflammation; unlikely to contribute significantly to near-term cardiovascular risk
MODERATE	200 - 235 ng/mL	Moderate vascular inflammation; consider additional risk factors (e.g., LDL, diabetes, coronary artery disease, metabolic syndrome, carotid stenosis etc.)
HIGH RISK	> 235 ng/mL	High likelihood of unstable plaque; strongly linked to stroke and coronary events, independent of LDL. Consider intensifying lipid lowering therapy and lifestyle interventions

- Lp-PLA2 is a novel Biomarker of vascular-specific inflammation and plays a significant role in atherosclerosis and provides information about atherosclerotic plaque inflammation.
- It is vascular specific unlike other inflammatory markers like hsCRP, that measure systemic inflammation.
- The LP-PLA2 test, also known as the PLAC test, measures lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme linked to LDL cholesterol, in the blood. LDL transports Lp-PLA2 towards the coronary artery walls and triggers an inflammatory reaction and may result in plaque formation and rupture. Therefore, Lp-PLA2 levels above a certain threshold signals an elevated risk of cardiovascular disease and ischemic stroke.
- The test can also be used to assess the risk of cardiovascular disease in individuals who are already at a moderate to high risk due to factors like diabetes, high LDL, family history of heart disease at younger age, metabolic syndrome, chronic kidney disease, smoking, etc.
- An elevated value of Lp-PLA2 is suggestive of more aggressive lipid lowering therapy to reduce the risk of CVD events.
- This test can be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for coronary heart disease and ischemic stroke associated with atherosclerosis.

Reference:

1. Madjid, M., Ali, M., & Willerson, J. T. (2010). Lipoprotein-Associated Phospholipase A2 as a novel risk marker for cardiovascular disease: A Systematic Review of the literature.
2. Charniot, J., et al (2012). Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. *International Journal of Cardiology*, 168(1), 132–138.
3. Davidson, M. H., et al (2008). Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines. *The American Journal of Cardiology*, 101(12), S51–S57.

***** End Of Report *****

DR. MUKTA SEHGAL
PH.D.(BIOCHEMISTRY)

DR. ARJUN DANG
M.D. (PATHOLOGY)

DR. MANAVI DANG
M.D. (PATHOLOGY)



CONDITIONS OF REPORTING



- ▶ In case of alarming or unexpected test results you are advised to contact the laboratory immediately for further discussions and action. Laboratory results are meant to be correlated with the patient's clinical history.
- ▶ The report will carry the name and age provided at the time of registration.
- ▶ Reporting of tests will be as per defined laboratory turn around time for each test. The same will be informed to the patient during first point of contact i.e. registration or phlebotomy as the case may be.
- ▶ Test results & reference ranges vary depending on the technology and methodology used.
- ▶ Rarely a second sample may be requested for an indeterminate result or any other pre-analytical / analytical reason.
- ▶ Reports can be received either as a hard copy or an email on your personal ID. Reports can also be delivered via courier. Payments can be made online on our website. Only reports with no pending payments are mailed, uploaded or dispatched.
- ▶ Reports can also be accessed via Dr. Dangs lab website or through the Dr. Dangs mobile application on IOS and android using the unique ID and password provided to you during registration or received by you via SMS.
- ▶ Home collection sample facility is provided with prior appointment. Request for same to be given on 999-999-2020, booked online on www.drdangslab.com or through the Dr. Dangs mobile application on IOS and android.
- ▶ A digital invoice for tests performed is available on our website and can be accessed by using the unique I.D. and password provided.
- ▶ To maintain confidentiality, certain reports may not be mailed at the discretion of the management.
- ▶ In compliance with government regulations, Dr. Dangs Lab will report all notifiable diseases to the designated government health authorities.
- ▶ In case of any queries pertaining to your test results or to provide feedback/suggestions please call us on 01145004200 or mail us at info@drdangslab.com.
- ▶ 48 hour notice is required for the issuing of slides and blocks.
- ▶ Test results are not valid for medico legal purposes.
- ▶ The courts (forums) at Delhi shall have exclusive jurisdiction in all disputes/claims consuming the tests and/or results of the tests.
- ▶ *For any changes in timings, please visit our website.

SAMPLE REPORT

DISCOVER

YOUR HEALTH TESTS. TAILOR-MADE

Customize Your Test Package



www.discoverbydrdangs.com

DR. DANGS LAB LLP

C2/1, AUROBINDO MARG, S.D.A., NEW DELHI-110016

GURUGRAM | NEW FRIENDS COLONY | PUNJABI BAGH | KAMLA NAGAR | VASANT KUNJ | GREATER KAILASH - 1
WWW.DRDANGSLAB.COM | INFO@DRDANGSLAB.COM | 999-999-2020, 011-45004200 (Sunday Closed)